LitAlert ~~ GeneLit.com

    • Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system.
    • Higashigawa S, Matsubayashi H, Kiyozumi Y, Kado N, Nishimura S, Oishi T, Sugino T, Fushiki K, Shirasu H, Yasui H, Mamesaya N, Fukuzaki N, Kunitomo K, Horiuchi Y, Kenmotsu H, Serizawa M.
    • Jpn J Clin Oncol. 2022 Apr 12:hyac046. doi: 10.1093/jjco/hyac046. Epub ahead of print.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2022 Apr 11.

    Identifier: NCT04367675: INO 5401 Vaccination in BRCA1/2 Mutation Carriers. (ClinicalTrials.gov)

    • Predicting Response to Anthracyclines in Ovarian Cancer.
    • Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N.
    • Int J Environ Res Public Health. 2022 Apr 2;19(7):4260. doi: 10.3390/ijerph19074260.
    • BRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma.
    • Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ.
    • Int J Mol Sci. 2022 Mar 29;23(7):3754. doi: 10.3390/ijms23073754.
    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.